New drug combo targets tough prostate cancer in understudied groups

NCT ID NCT06392841

Terminated Disease control Sponsor: Qian Qin Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 15 times

Summary

This study was designed to test a combination of two drugs (niraparib and abiraterone plus prednisone) in Hispanic/Latino and Black patients with metastatic hormone-sensitive prostate cancer that has certain gene mutations. The goal was to see if the treatment could lower PSA levels significantly after 24 weeks. However, the study was withdrawn before enrolling any participants, so no results are available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

Explore the condition pages connected to this study.

BRCA1 GENE MUTATION BRCA1 GENE MUTATION BRCA2 GENE MUTATION BRCA2 GENE MUTATION BRIP1 GENE MUTATION CHEK2 GENE MUTATION DELETERIOUS HRR GENE MUTATION FANCA GENE MUTATION METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) PALB2 GENE MUTATION RAD51B GENE MUTATION RAD51B GENE MUTATION RAD54L GENE MUTATION RAD54L GENE MUTATION